Skip to content

Polaryx Therapeutics, Inc. PLYX Deferred Tax Liabilities, Net

Deferred Tax Liabilities, Net at other companies

Mondelez International logo
Mondelez InternationalMDLZ
$3.19B+3.3%
Ametek logo
AmetekAME
$674.85M-10.4%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$277M
Imperial Oil logo
Imperial OilIMO
$4.42B-1.5%
Duke Energy logo
Duke EnergyDUK
$11.42B+8.2%
Williams Companies logo
Williams CompaniesWMB
$4.38B+13.8%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$115.64M

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxLiabilities.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's deferred tax liabilities, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's deferred tax liabilities, net?
Polaryx Therapeutics, Inc. (PLYX) reported deferred tax liabilities, net of $250K in Q4 2025.